Summit Therapeutics Reportedly Makes $15B AstraZeneca Licensing Talks for Lung Cancer Drug
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts.
Summit Therapeutics Inc. (SMMT)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Lansdowne Partners Alex Snow | 0 | $0 | 0% | |
| 2. | Renaissance Technologies Jim Simons | 0 | $0 | 0% | |
| 3. | Polar Capital Brian Ashford-Russell And Tim Woolley | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $3.71 | 20,000 | $74,200.00 | 50,000 | 2024-03-27 | Filing | |
| $3.75 | 30,000 | $112,500.00 | 30,000 | 2024-03-26 | Filing | |
| $3.72 | 34,321 | $127,674.12 | 24,923,800 | 2024-03-27 | Filing | |
| $3.72 | 26,000 | $96,720.00 | 520,814 | 2024-03-27 | Filing | |
| $3.75 | 100,000 | $375,000.00 | 354,958 | 2024-03-26 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $4.44 | 13,713 | $60,885.72 | 0 | 2020-11-30 | Filing | |
| $4.39 | 29,569 | $129,807.91 | 0 | 2020-11-27 | Filing | |
| $4.32 | 12,070 | $52,142.40 | 0 | 2020-11-25 | Filing | |
| $4.21 | 11,374 | $47,884.54 | 0 | 2020-11-24 | Filing | |
| $4.40 | 6,987 | $30,742.80 | 0 | 2020-11-23 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 843 | $16,261 | 0% | |
| 2. | 654 | $12,295 | 0% | |
| 3. | 453 | $8,738 | 0% | |
| 4. | 195 | $3,762 | 0% | |
| 5. | 70 | $1,350 | 0% |
News See All
Revolution Medicines, Summit Therapeutics Partner on RAS Inhibitor/Ivonescimab Combinations for Solid Tumors
Revolution Medicines Inc. (NASDAQ:RVMD) is one of the best high short interest stocks with huge upside potential. On June 30, Revolution Medicines and Summit Therapeutics Inc.
11 Best Hot Stocks to Buy According to Wall Street Analysts
On July 1, Ralph Schlosstein, Evercore's chairman emeritus and BlackRock's co-founder, joined 'Closing Bell Overtime' on CNBC to talk about his outlook for markets heading into the second half of the ...
Summit Therapeutics (SMMT) Rated Buy on Ivonescimab’s Cancer-Fighting Potential
Summit Therapeutics Inc. (NASDAQ:SMMT) ranks among the 30 stocks expected to beat the market by 20 percentage points this year. Analysts at H.C.
30 Stocks Expected To Beat the Market By 20 Percentage Points This Year
The US stock market has gone through a turbulent journey this year. Following a correction in March and a lull in April, the S&P 500 recovered its losses in May and June.
H.C. Wainwright Sticks With Bullish Call on Summit Therapeutics, $44 Target
H.C. Wainwright isn’t backing off Summit Therapeutics (NASDAQ: SMMT).
Why Summit Therapeutics Inc. (SMMT) Crashed On Wednesday
We recently published a list of Investors Are Dumping These 10 Stocks.
Why Summit Therapeutics Inc. (SMMT) Skyrocketed On Tuesday
We recently published a list of 10 Stocks Leaving Wall Street in The Dust.
Truist Sticks to $35 Target on Summit (SMMT) Despite Shifting Deal Landscape
In a June 2 report, Truist Securities analyst Asthika Goonewardene weighed in on the implications of Bristol-Myers Squibb’s newly announced partnership with BioNTech SE on Summit Therapeutics Inc.
Why Summit Therapeutics Inc. (SMMT) Crashed Last Week
We recently published a list of These 10 Stocks Just Rocked The Market. In this article, we are going to take a look at where Summit Therapeutics Inc.
Billionaire Hedge Funds
